期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

治疗痛风新药非布司他的临床研究进展 被引量：20

Advance in clinical research of febuxostat in the treatment of gout
原文传递
导出
摘要 痛风是成人常见的炎症性关节炎类型之一。选择性黄嘌呤氧化酶抑制剂非布司他是一种高尿酸血症和痛风治疗新药。本文综述其药动学、作用机制及临床研究。 Gout is one of the most common inflammatory arthritis in adults. Febuxostat is a new drug for the treatment of hyperuricemia and gout through inhibiting xanthine oxidase. This review summarizes its pharmacokinetic, pharmacological effects and clinical studies.
作者 张源潮 户中丹 杨兆文 王威严
机构地区 山东大学附属省立医院风湿免疫科
出处 《世界临床药物》 CAS 2014年第9期519-522,共4页 World Clinical Drug
关键词 非布司他 痛风 降尿酸药物 febuxostat gout hypouricemic drug
分类号 R983.2 [医药卫生—药品] R593.2 [医药卫生—内科学]
  • 相关文献

参考文献19

  • 1Mccarty DJ, Hollander JL. Identification of urate crystals in gouty synovial fluid [J] . Ann Intern Med, 1961, 54: 452-460.
  • 2Harrold LR, Saag KG, Yood RA, et al. Validity of gout diagnoses in administrative data [J] . Arthritis Rheum, 2007, 57 (1): 103-108.
  • 3Wallace KL, Riedel AA, Joseph-Ridge N, et al. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population [J]. J Rheumatol, 2004,31 (8): 1582-1587.
  • 4Saag KG, Choi H. Epidemiology, risk factors, and lifestyle modifications for gout [J] . Arthritis Res Ther, 2006, 8 (1) : S2.
  • 5Roddy E, Zhang W, Doherty M. The changing epidemiology of goutJ]. Nat Clin Pract Rheumatol, 2007, 3 (8): 443-449.
  • 6Annemans L, Spaepen E, Gaskin M, et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005 [J]. Ann Rheum Dis, 2008, 67 (7) : 960-966.
  • 7Zhang W, Doherty M, Bardin T, et al . EULAR evidence based recommendations for gout. Part II : management. Reportof a task force of the standing committee for international clinical studies including therapeutics (ESCISIT) [J]. Ann Rheum Dis, 2006,65 (10): 1312-1324.
  • 8European Medicines Agency. Adenuric'P' (febuxostat): EPARproduct information [EB!O L J. [2011-01-22 J [2014-06- 22 J . http://www. ema. europa. eu! docs! en _ G B! document_library! EPAR-Product Information/human/000777/WC500021812. pdf.
  • 9Takeda Pharmaceuticals North America, Inc. ULORICTM (febuxostat): prescribing information [EB/OLJ . [2011-0 1-22J [2014-06-22 J. http://general.takedapharm. com/content/ file/PI.pdf?applicationCode=3f8eb050-0baf-42e3-905fd 1 f40687 5b9c&fileTypeCode=ULORICPI.
  • 10Okamoto K, Eger BT, Nishino T, et at. An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition [J]. J Bioi Chern, 2003, 278 (3): 1848-1855.

同被引文献131

  • 1黄亮,蒋学华,张勤,兰轲.生理药动学模型研究利多卡因静脉给药的体内过程[J].中国药学杂志,2006,41(8):585-589. 被引量：13
  • 2朱深银,周远大,杜冠华.防治痛风药物的研究进展[J].医药导报,2006,25(8):803-806. 被引量：31
  • 3Sehlesinger N, Alten RE, Bardin T, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised multicentre, active-controlled, double-blind trials and their initial extensions[J]. Ann Rheum Dis., 2012, 71(11): 1839-1848.
  • 4Schumacher HR Jr, Evans RR, Sang KG, et al. Rilonacept (interleukin-lTrap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study[J]. Arthritis Care Res (Hoboken), 2012, 64(10): 1462-1470.
  • 5So A, De Smedt T, Revaz S, et al. A pilot study of IL-1 inhibition by anakinra in acute gout[J]. Arthritis Res Ther, 2007, 9(2):R28.
  • 6Sundy J, Perez-Ruiz F, Krishnan E, et al. Efficacy and safety of lesinurad (rdea594), a novel uricosuric agent, given in combination with allopurinol in allopurinol-refractory gout patients: preliminary results from the randomized, double-blind, placebo-controlled, phase 2b extension study [EB/OL]. [2015-05-20]. https ://acr.confex.com/acr/2O l l /webprogram/ Paper23977.html.
  • 7Truglio JJ, Theis K, LeimkiJhler S, et al. Crystal structures of the active and alloxanthine-inhibited forms of xanthine dehydrogenase from Rhodobacter capsulatus[J]. Structure 2002, 10(1): 115-125.
  • 8Okamoto K, Eger BT, Nishino T, et al. An extremely poten inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition[J]. Biol Chem, 2003, 278(3): 1848-1855.
  • 9Report on the deliberation results[EB/OL]. (2013-05-08 [2015-04-21 ]. http://www.pmda.go.jp/files/000153624.pdf.
  • 10Hollister AS, Becker M, TerkeltaubR, et al. BCX4208 show synergistic reductions in serum uric acid in gout patients when combined with allopurinol[EB/OL]. [2015-04-21]. http://www.biocryst.com/PDFs/BCRX_B CX4208_Hollister EULAR_2011 _Poster.pdf.

引证文献20

二级引证文献118

世界临床药物
2014年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部